Sodium polystyrene sulfonate
سدیم پلیاستایرن سولفونات (کیاگزالات)
🧪 VariousCation-exchange resin
Market / country: 🇺🇸 USA
Kayexalate (US)
🧮 Dose calculator
Hyperkalaemia · Regimen source: FDA SPS suspension · Dosage and Administration
- • Average 15–60 g/day. Separate from other oral drugs by ≥3 h (6 h with gastroparesis). Upright position. Each 60 mL contains 1,500 mg sodium. Children: lower doses based on 1 mEq K per g resin. FDA SPS suspension · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypokalaemia; resin hypersensitivity; obstructive bowel disease; oral or rectal use in neonates. FDA SPS suspension · Contraindications
Warnings
- • Intestinal necrosis (sometimes fatal) and serious GI events; avoid with sorbitol. FDA SPS suspension · Warnings
Formulations
- 15 g / 60 mL oral suspension — suspension 🇺🇸 USA FDA SPS suspension · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA SPS suspension · Pregnancy
“Animal reproduction studies have not been conducted with sodium polystyrene sulfonate.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA SPS suspension · Nursing Mothers
“Because many drugs are excreted in human milk, caution should be exercised when sodium polystyrene sulfonate is administered to a nursing woman.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA SPS suspension · Pediatric Use
“The effectiveness of Sodium Polystyrene Sulfonate Suspension, USP in pediatric patients has not been established.”
- 👴 Older adultsNo data
The source for this drug has no section for this group.
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA214912
- DailyMed (FDA label)FDA SPS suspension
- MedlinePlus (NIH)Sodium Polystyrene Sulfonate
- WHO ATC/DDDV03AE01
- Darooyab (Iran)Sodium-Polystyrene-Sulfonate
🇮🇷 Registered in Iran Darooyab · G-1983/Sodium-Polystyrene-Sulfonate
Dosage forms with Iranian generic codes, per Darooyab.
- 05242 · SODIUM POLYSTYRENE SULFONATE 15G SACHET · ساشه سدیم پولیستیرن سولفونات ۱۵ گرم
- 01156 · SODIUM POLYSTYRENE SULFONATE 454 G POW FOR SUSP · پودر برای تهیه سوسپانسیون خوراکی سدیم پولیستیرن سولفونات ۴۵۴ گرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA SPS suspension · How SuppliedFDA SPS suspension · Dosage and AdministrationFDA SPS suspension · ContraindicationsFDA SPS suspension · WarningsFDA SPS suspension · PregnancyFDA SPS suspension · Nursing MothersFDA SPS suspension · Pediatric UseFDA SPS suspension · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1983/Sodium-Polystyrene-Sulfonate
- Clinical review⚠ Unverified